Apo-Amitriptyline: Affected lots may exceed the interim acceptable intake limit for NNORT
Brand(s)
Summary
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Apo |
Apo-Amitriptyline |
DIN 02403137 |
Tablet |
Amitriptyline Hydrochloride 10 mg |
RN6384, RR0265, RR0266, RV1644, RV1645, RW8597, RW8598, TA6008, TA6009, TF8585, TF8586, TF8587, TF8588, TF8589, TW2842, TW2843 |
Apo |
Apo-Amitriptyline |
DIN 02403145 |
Tablet |
Amitriptyline Hydrochloride 25 mg |
RM0519, RM8130, RR0780, RR0781, RV1656, RV1657, RW8691, TA6061, TA6062, TF8602, TF8603 |
Issue
Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-nortriptyline (NNORT)
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Previous recalls or alerts
Background
Depth of recall: Wholesalers, Retailers, Healthcare Establishments
Details
Apotex Inc
150 Signet Drive, Toronto, ON Canada M9L 1T9
Get notified
Receive notifications for new and updated recalls and alerts by category.